TISSIUM, a medical technology company based in Paris, has announced a €60 million financing package made up of a completed €30 million Series D2 round and a financing facility of up to €30 million from the European Investment Bank.
The Series D2 financing was completed at the end of 2025 with backing from new and existing international investors. The EIB facility will be released in three €10 million tranches tied to commercial, clinical and financing milestones, combining dilutive capital and venture debt.
The funding is set to support TISSIUM’s commercial and clinical activities, pipeline development and platform expansion. It also comes as the company moves ahead with the US rollout of COAPTIUM CONNECT and advances clinical programs across multiple surgical applications.
TISSIUM develops biomorphic programmable polymers for tissue reconstruction, positioning the company at the intersection of advanced materials and medical technology.
The Series D2 financing was completed at the end of 2025 with backing from new and existing international investors. The EIB facility will be released in three €10 million tranches tied to commercial, clinical and financing milestones, combining dilutive capital and venture debt.
The funding is set to support TISSIUM’s commercial and clinical activities, pipeline development and platform expansion. It also comes as the company moves ahead with the US rollout of COAPTIUM CONNECT and advances clinical programs across multiple surgical applications.
TISSIUM develops biomorphic programmable polymers for tissue reconstruction, positioning the company at the intersection of advanced materials and medical technology.